source
- Latigo Biotherapeutics targets non-opioid pain market with $247 M IPOLatigo Biotherapeutics announced details of its planned initial public offering, aiming to raise roughly $247 million to advance its pipeline of non-opioid pain treatments. The company intends to…
- Eli Lilly expands early-access program for experimental obesity drug retatrutideEli Lilly announced it will broaden its early-access initiative for retatrutide, an investigational drug targeting obesity. The company said the program will let additional patients apply for the…